Express Scripts Holding Company Company Profile (NASDAQ:ESRX)

Express Scripts Holding Company trades on the NASDAQ under the ticker symbol "ESRX."

Express Scripts Holding Company (NASDAQ:ESRX) posted its quarterly earnings data on Monday, April, 24th. The company reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.01. The firm earned $24.65 billion during the quarter, compared to analysts' expectations of $24.95 billion. Express Scripts Holding Company had a net margin of 3.42% and a return on equity of 25.64%. The company's quarterly revenue was down .6% compared to the same quarter last year. During the same quarter last year, the company posted $1.22 EPS. View Express Scripts Holding Company's Earnings History.

Express Scripts Holding Company is scheduled to release their next quarterly earnings announcement on Monday, July, 24th 2017. View Earnings Estimates for Express Scripts Holding Company.

Express Scripts Holding Company issued an update on its FY17 earnings guidance on Monday, April, 24th. The company provided earnings per share guidance of $6.90-7.04 for the period, compared to the Thomson Reuters consensus estimate of $6.93. Express Scripts Holding Company also updated its Q2 guidance to $1.70-1.74 EPS.

17 analysts have issued 1-year price objectives for Express Scripts Holding Company's stock. Their forecasts range from $52.00 to $88.00. On average, they anticipate Express Scripts Holding Company's stock price to reach $70.75 in the next year. View Analyst Ratings for Express Scripts Holding Company.

Here are some recent quotes from research analysts about Express Scripts Holding Company stock:

• 1. Jefferies Group LLC analysts commented, "We believe ESRX remains a Buy given our view that company fundamentals, including its FCF, are stable and that the stock's valuation is attractive at 9x FY18 P/E. That said, we recognize that headlines surrounding drug pricing pressure and the overhang from ESRX's Anthem contract will drive continued stock volatility NT." (2/17/2017)
• 2. According to Zacks Investment Research, "Express Scripts’ fourth-quarter 2016 results were mixed, wherein adjusted earnings topped the Zacks Consensus Estimate, revenues beat the same. In the past three months, the company has underperformed the broader industry with respect to price performance. While the company’s guidance for 2017 was encouraging, tough competition in the Pharmacy Benefit Management space and the persistent drug pricing issue are expected to affect the share price. Express Scripts stands to benefit from increased generic utilization, shift toward mail orders, strong specialty growth and an aging population. The company is focused on the development of both specialty drugs and generics, which are expected to account for 50% of the total drug expenditure by 2018. Further, its SafeGuardRx suite of products is designed to better manage specialty spend in turn, establishing a higher standard for patient outcomes." (2/16/2017)
• 3. Credit Suisse Group analysts commented, "We continue to believe ESRX will seek to buy Rite Aid’s PBM unit from Walgreens if the deal closes successfully and possibly add its generic purchasing clout to Walgreen’s buying consortium for added economics. Derivatives: At a time when hapless politicians are wringing their wrists about out of control drug costs, we cite another example of a large government payor tapping PBM solutions for greater savings. As opposed to Anthem, TRICARE utilizes a number of ESRX’s cost management tools in addition to a preferred pharmacy network to better manage its trend. We see the PBM model as more rather than less relevant to the current situation, and we see longer-term enhanced roles for PBMs in Medicare part D and B. Separately, we see AmerisourceBergen as benefiting from the news as Walgreen’s supplier, while Cardinal Health stand to lose some share as CVS’s partner." (10/3/2016)

Express Scripts Holding Company saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 37,640,819 shares, an increase of 8.1% from the May 15th total of 34,835,030 shares. Based on an average trading volume of 3,757,884 shares, the days-to-cover ratio is presently 10.0 days. Currently, 6.4% of the shares of the company are sold short.

Some companies that are related to Express Scripts Holding Company include Thermo Fisher Scientific (TMO), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Stryker Corporation (SYK), Shire PLC (SHPG), Aetna (AET), Anthem (ANTM), Fresenius SE (FSNUY), Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Boston Scientific Corporation (BSX), McKesson Corporation (MCK), Intuitive Surgical (ISRG), Humana (HUM), Baxter International (BAX), Vertex Pharmaceuticals Incorporated (VRTX), Teva Pharmaceutical Industries Limited (TEVA) and HCA Holdings (HCA).

Express Scripts Holding Company's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (6.78%), State Street Corp (4.56%), Barrow Hanley Mewhinney & Strauss LLC (2.97%), Bank of New York Mellon Corp (1.85%), Macquarie Group Ltd. (1.85%) and Veritas Asset Management LLP (1.22%). Company insiders that own Express Scripts Holding Company stock include Christopher A Mcginnis, Everett Neville, Mahon Thomas P Mac, Phyllis S Anderson and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts Holding Company.

Express Scripts Holding Company's stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, Wedgewood Partners Inc., Brave Warrior Advisors LLC, Manning & Napier Advisors LLC, Schroder Investment Management Group, Teachers Advisors LLC, FIL Ltd and Glen Harbor Capital Management LLC. Company insiders that have sold Express Scripts Holding Company stock in the last year include Christopher A Mcginnis, Everett Neville, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts Holding Company.

Express Scripts Holding Company's stock was acquired by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., Renaissance Technologies LLC, Baupost Group LLC MA, Ameriprise Financial Inc., Barrow Hanley Mewhinney & Strauss LLC, Vanguard Group Inc., Artisan Partners Limited Partnership and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Express Scripts Holding Company.

Shares of Express Scripts Holding Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Express Scripts Holding Company stock can currently be purchased for approximately $65.21.